Juvisé Pharmaceuticals Formally Approved the Appointments of Frédéric Mascha as Executive Chairman and Chairman of the Supervisory Committee and the Nomination of Renaud Sermondade as the Group’s New CEO

Contributed by: Business Wire

Images

From left to right: Frédéric Mascha and Renaud Sermondade

Business Wire embedded0

Tags

Other Health

Banking

Accounting

Professional Services

Pharmaceutical

Oncology

Chemicals/Plastics

Neurology

Finance

Consulting

Manufacturing

Health

Board of Directors meeting held on April 15, 2026

More Like This

From left to right: Chris Perkin, Executive Chairman of the Board (Altasciences), and Marie-Hélène Raigneau, Chief Executive Officer (Altasciences).

Altasciences Announces Chris Perkin Appointed Executive Chairman; Marie-Hélène Raigneau Appointed Chief Executive Officer

Generational Change at JAB: Joachim Creus Appointed CEO

François Ravenelle, PhD, President and Chief Executive Officer of Innospera Pharma

François Ravenelle, PhD Appointed President and CEO of Innospera Pharma to Lead Next Phase of Growth

Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton

Jérôme Vailland 4P-Pharma Chief Financial Officer (Photo: Business Wire)

Jérôme Vailland Joins 4P-Pharma as Chief Financial Officer

Vertex Appoints Michel Lagarde to its Board of Directors

PR Newswire associated0

mAbxience Appoints Jurgen Van Broeck as New CEO

Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer